Pharmacokinetics of Alfentanil in Patients Treated with Either Cimetidine or Ranitidine
Tóm tắt
The pharmacokinetics of alfentanil were studied after single dose intravenous administration of 125 μg/kg to 19 intensive care unit patients who were divided into 3 groups. Group I was given oral antacid, and groups II and III were given, respectively, cimetidine 1200 mg/day IV and ranitidine 300 mg/day IV for 48 hours before administration of alfentanil. Alfentanil plasma concentrations were determined over the 8 hours following drug administration using a radio-immunoassay. Pharmacokinetic parameters were calculated using a noncompartmental analysis. In group II, alfentanil plasma concentrations were significantly higher than in the other groups. In addition, significant changes involving the elimination half-life (142.3 ± 35 vs 81.14 ± 11 and 88.1 ± 33 minutes), total clearance (1.27 ± 0.5 vs 3.56 ± 1.17 and 2.74 ± 1 ml/kg/min) and total volume of distribution related to the pseudo distribution phase (226 ± 73 vs 336 ± 76 and 271 ± 61 ml/kg) were found in group II vs groups I and III. These results suggest that pretreatment with cimetidine alters alfentanil pharmacokinetics after single dose administration. In contrast, ranitidine does not appear to have a significant effect.
Tài liệu tham khảo
Alvan G. Clinical consequences of polymorphic drug oxidation. Fundamental and Clinical Pharmacology 5: 209–228, 1991
Bell JA, Gower AJ, Martin LE, Mills ENC, Smith WP. Interaction of H2 receptor antagonists with drug-metabolising enzymes. Biochemical Society Transactions 9: 113–114, 1981
Bovill JG, Sebel PS, Blackburn CL, Heykants J. The pharmacokinetics of alfentanil (R 39209): a new opioid analgesic. Anesthesiology 57: 439–443, 1982
Bower S, Hull CI. Comparative pharmacokinetics of fentanyl and alfentanil. British Journal of Anaesthesia 54: 871–891, 1982
Breen KJ, Bury R, Desmond PV, Mashford ML, Morphett B, et al. Effects of cimetidine and ranitidine on hepatic drug metabolism. Clinical Pharmacology and Therapeutics 31: 297–300, 1982
Camu F, Gepts E, Rucquoi M, Heykants J. Pharmacokinetics of alfentanil in man. Anesthesia and Analgesia 61: 657–661, 1982
Chauvin M, Bonnet F, Montembault C, Levron JC, Viars P. The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurements of alfentanil hepatic extraction coefficient. Anesthesia and Analgesia 65: 999–1003, 1986
Dayer P, Leeman T, Striberni R. Dextromorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P 450 db 1 activity. Clinical Pharmacology and Therapeutics 45: 34–40, 1989
Feely J, Wilkinson GR, McAllister CB, Wood AJJ. Increased toxicity and reduced clearance of lidocaine by cimetidine. Annals of Internal Medicine 96: 592–594, 1982
Feely J, Wilkinson GR, Wood AJJ. Reduction of liver blood flow and propranolol metabolism by cimetidine. New England Journal of Medicine 304: 692–695, 1981
Feely J, Wood AJJ. Effect on apparent liver blood flow of histamine receptor blockers and inhibition of prostaglandin synthesis. Clinical Pharmacology and Therapeutics 33: 91–94, 1983
Ferrier C, Marty J, Bouffard Y, Haberer JP, Levron JC, et al. Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology 62: 480–484, 1985
Gibaldi M, Perrier D. Multicompartment models. In Gibaldi & Perrier (Eds) Pharmacokinetics, 2nd ed., pp. 45–96, Marcel Dekker, New York, 1982
Guay DRP, Meatherall RC, Chalmers JL, Grahame GR. Cimetidine alters pethidine disposition in man. British Journal of Clinical Pharmacology 18: 907–914, 1984
Henthorn TK, Avram MJ, Krejcie TC. Alfentanil clearance is independent of the polymorphic debrisoquine-hydroxylase. Anesthesiology 71: 635–639, 1989a
Henthorn TK, Spina E, Dumont E, Von Bahr C. In vitro inhibition of polymorphic human liver cytochrome P 450 isozyme by narcotic analgesics. Anesthesiology 70: 339–342, 1989b
Lauven PM, Stoeckel H, Schüttler J, Schwilden H. Verhinderung des fentanyl-rebound-phänomens durch cimetidin-medikation. Anaesthesist 30: 467–471, 1981
Lavrijsen KLM, van Houdt JMG, van Dydk DMJ, Hendricks JJM, Woestenborghs RJH, et al. Is the metabolism of alfentanil subject to debrosoquine polymorphism? A study using human liver microsomes. Anesthesiology 69: 535–540, 1988
Levron JC, d’Enfert J, Flaisler B, Bouillardien JL, Landais A, et al. Influence d’une prémédication par la cimétidine sur la pharmacocinetique de l’alfentanil au cours d’interventions chirurgicales. Journal de Pharmacologic Clinique 4: 91–96, 1985
Meuldermans WEG, van Peer A, Hendrickx J, Woestenborghs R, Lauwers W, et al. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 69: 527–534, 1988
Michiels M, Hendriks R, Heykants J. Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetics profile in man. Journal of Pharmacy and Pharmacology 35: 86–93, 1983
Niemegeers CJE, Janssen PAS. Alfentanil (R 39209) a particularly short-acting intravenous narcotic analgesic in rats. Drug Development and Research 1: 83–88, 1981
Rendic S, Kajfez F, Ruf HH. Characterization of cimetidine, ranitidine, and related structures interaction with cytochrome P 450. Drug Metabolism and Disposition 11: 137–142, 1983
Schellens JH, van der Wart JH, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a ‘cocktail’ study design. Journal of Pharmacology and Experimental Therapeutics 249: 638–645, 1989
Shafer A, Sung ML, White PF. Pharmacokinetics and pharmacodynamics of alfentanil infusion during general anesthesia. Anesthesia and Analgesia 65: 1021–1028, 1986
Smith SR, Kendall MJ. Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions. Clinical Pharmacokinetics 15: 44–56, 1988
Somogyi A, Gugler R. Drug interactions with cimetidine. Clinical Pharmacokinetics 7: 26–41, 1982
Speeg Jr KV, Patwardhan RV, Avant GR, Mitchell MC, Schenker S. Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology 82: 89–96, 1982
Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of new oxidative drug metabolism polymorphism. Clinical Pharmacology and Therapeutics 36: 773–780, 1984
Yate PM, Sebel PS. Abnormal alfentanil pharmacokinetics (letter). British Journal of Anaesthesia 59: 808, 1987